Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q9H477

UPID:
RBSK_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q9H477; A9UK04; B4DV96

BACKGROUND:
The enzyme Ribokinase is fundamental in the metabolic pathway, facilitating the conversion of ribose to D-ribose-5-phosphate using ATP and magnesium. This reaction is vital for the production of nucleotides and certain amino acids, underscoring Ribokinase's importance in both energy metabolism and genetic material synthesis.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Ribokinase offers a promising avenue for the development of novel therapeutic approaches. Given its crucial role in metabolism and nucleotide synthesis, targeting Ribokinase could lead to breakthroughs in treating metabolic diseases and improving cellular function.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.